Ocular effects of apraclonidine in Horner syndrome

Archives of Ophthalmology

Volumn 118, Issue 7, 2000, Pages 951-954

  Morales, Jose ^a   Brown, Sandra M ^a,c   Abdul Rahim, Aziz S ^a   Crosson, Craig E ^a,b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; APRACLONIDINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EYE; HORNER SYNDROME; HUMAN; INTRAOCULAR PRESSURE; MYDRIASIS; PRIORITY JOURNAL; PUPIL;

ADRENERGIC ALPHA-AGONISTS; AQUEOUS HUMOR; CILIARY BODY; CLONIDINE; COHORT STUDIES; HORNER SYNDROME; HUMANS; INTRAOCULAR PRESSURE; OPHTHALMIC SOLUTIONS; PUPIL; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 0033940946     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Robin AL. Short-term effects of unilateral 1% apraclonidine therapy. Arch Ophthalmol. 1988;106:912-915.
2. Maus TL, Nau C, Brubaker RF. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents. Arch Ophthalmol. 1999; 117:586-591.
3. Burke J, Crosson C, Potter D, Can UK-14, 304-18 lower IOP in rabbits by a peripheral mechanism? Curr Eye Res. 1989;8:547-552.
4. Potter DE, Crosson CE, Heath AR, Ogidigben MJ. Review: alpha 2 and DA2 agonists as antiglaucoma agents: comparative pharmacology and clinical potential. J Ocul Pharmacol. 1990;6:251-257.
5. Campbell WR, Potter DE. Centrally mediated ocular hypotension: potential role of imidazoline receptors. Ann N Y Acad Sci. 1995;763:463-485.
6. Thompson H, Miller N. Disorders of pupillary function, accommodation, and lacrimation. In: Miller N, Newman N, eds. Walsh and Hoyt's Clinical Neuro-Ophthalmology. Baltimore, Md: Williams & Wilkins; 1998:961-1040.
7. Crosson CE, Heath AR, DeVries GW, Potter DE. Pharmacological evidence for heterogeneity of ocular alpha 2 adrenoceptors. Curr Eye Res. 1992;11:963-970.
8. Wiederholt M, Schafer R, Wagner U, Lepple-Wienhues A. Contractile response of the isolated trabecular meshwork and ciliary muscle to cholinergic and adrenergic agents. Ger J Ophthalmol. 1996;5:146-153.
9. Lin SL, Liang SS. Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution. J Ocul Pharmacol Ther. 1995;11:267-278.
10. Yuksel N, Guler C, Caglar Y, Elibol O. Apraclonidine and clonidine: a comparison of efficacy and side effects in normal and ocular hypertensive volunteers. Int Ophthalmol. 1992;16:337-342.
11. Jampel HD, Robin AL, Quigley HA, Pollack IP. Apraclonidine: a one-week dose-response study. Arch Ophthalmol. 1988;106:1069-1073.
12. Gharagozloo NZ, Relf SJ, Brubaker RF. Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145). Ophthalmology. 1988; 95:1217-1220.
13. Stewart WC, Laibovitz R, Horwitz B, Stewart RH, Ritch R, Kottler M. A 90-day study of the efficacy and side effects of 0.25% and 0.5% apraclonidine vs 0.5% timolol: Apraclonidine Primary Therapy Study Group. Arch Ophthalmol. 1996; 114:938-942.
14. Abrams DA, Robin AL, Pollack IP, deFaller JM, DeSantis L. The safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers. Arch Ophthalmol. 1987;105:1205-1207.
15. Langham ME, Weinstein GW. Horner's syndrome: ocular supersensitivity to adrenergic amines. Arch Ophthalmol. 1967;78:462-469.
16. Thompson HS, Mensher JH. Adrenergic mydriasis in Horner's syndrome: hydroxyamphetamine test for diagnosis of postganglionic defects. Am J Ophthalmol. 1971;72:472-480.
17. Wilhelm H, Ochsner H, Kopycziok E, Trauzettel-Klosinski S, Schiefer U, Zrenner E. Horner's syndrome: a retrospective analysis of 90 cases and recommendations for clinical handling. Ger J Ophthalmol. 1992;1:96-102.
18. Thompson BM, Corbett JJ, Kline LB, Thompson HS. Pseudo-Horner's syndrome. Arch Neurol. 1982;39:108-111.